Griseofulvin in the treatment of oral lichen planus: adverse drug reactions, but little beneficial effect.
An open trial was conducted of systemic griseofulvin in the treatment of oral lichen planus. Eleven patients completed the trial. Symptomatic benefit was noted in 21% of the twenty-three patients starting the trial, but there was no clinical improvement, and about one half of the group starting the trial suffered adverse drug reactions.
Matthews
R W
RW
University Department of Oral Medicine Surgery, and Pathology, Bristol Dental Hospital and School, UK.
Scully
C
C
D000284:Administration, Oral; D006118:Griseofulvin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006261:Headache / Q000139:chemically induced; D006801:Humans; D008010:Lichen Planus / Q000188:drug therapy* / Q000473:pathology; D009059:Mouth Diseases / Q000188:drug therapy* / Q000473:pathology; D009325:Nausea / Q000139:chemically induced; D013607:Tablets; D017211:Treatment Failure
D013607:Tablets; D006118:Griseofulvin